<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85821</article-id><article-id pub-id-type="doi">10.7554/eLife.85821</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Cryo-EM structure of the endothelin-1-ET<sub>B</sub>-G<sub>i</sub> complex</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-303233"><name><surname>Sano</surname><given-names>Fumiya K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8965-788X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-303234"><name><surname>Akasaka</surname><given-names>Hiroaki</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2118-0912</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-204283"><name><surname>Shihoya</surname><given-names>Wataru</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4813-5740</contrib-id><email>wtrshh9@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-212636"><name><surname>Nureki</surname><given-names>Osamu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1813-7008</contrib-id><email>nureki@bs.s.u-tokyo.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>Department of Biological Sciences, Graduate School of Science, The University of Tokyo</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Drew</surname><given-names>David</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f0yaq80</institution-id><institution>Stockholm University</institution></institution-wrap><country>Sweden</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Swartz</surname><given-names>Kenton J</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institute of Neurological Disorders and Stroke, National Institutes of Health</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>25</day><month>04</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85821</elocation-id><history><date date-type="received" iso-8601-date="2022-12-28"><day>28</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-23"><day>23</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2023-01-12"><day>12</day><month>01</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.01.12.523720"/></event></pub-history><permissions><copyright-statement>© 2023, Sano et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Sano et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85821-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85821-figures-v1.pdf"/><abstract><p>The endothelin ET<sub>B</sub> receptor is a promiscuous G-protein coupled receptor that is activated by vasoactive peptide endothelins. ET<sub>B</sub> signaling induces reactive astrocytes in the brain and vasorelaxation in vascular smooth muscle. Consequently, ET<sub>B</sub> agonists are expected to be drugs for neuroprotection and improved anti-tumor drug delivery. Here, we report the cryo-electron microscopy structure of the endothelin-1-ET<sub>B</sub>-G<sub>i</sub> complex at 2.8 Å resolution, with complex assembly stabilized by a newly established method. Comparisons with the inactive ET<sub>B</sub> receptor structures revealed how endothelin-1 activates the ET<sub>B</sub> receptor. The NPxxY motif, essential for G-protein activation, is not conserved in ET<sub>B</sub>, resulting in a unique structural change upon G-protein activation. Compared with other GPCR-G-protein complexes, ET<sub>B</sub> binds G<sub>i</sub> in the shallowest position, further expanding the diversity of G-protein binding modes. This structural information will facilitate the elucidation of G-protein activation and the rational design of ET<sub>B</sub> agonists.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>GPCR</kwd><kwd>Cryo-EM</kwd><kwd>Endothelin</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>21H05037</award-id><principal-award-recipient><name><surname>Nureki</surname><given-names>Osamu</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>22K19371</award-id><principal-award-recipient><name><surname>Shihoya</surname><given-names>Wataru</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>22H02751</award-id><principal-award-recipient><name><surname>Shihoya</surname><given-names>Wataru</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008664</institution-id><institution>Ono Medical Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Shihoya</surname><given-names>Wataru</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008657</institution-id><institution>Kao Foundation for Arts and Sciences</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Shihoya</surname><given-names>Wataru</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007449</institution-id><institution>Takeda Science Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Shihoya</surname><given-names>Wataru</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008732</institution-id><institution>Uehara Memorial Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Shihoya</surname><given-names>Wataru</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Platform Project for Supporting Drug Discovery and Life Science Research</institution></institution-wrap></funding-source><award-id>JP22ama121012 (support number 3272)</award-id><principal-award-recipient><name><surname>Shihoya</surname><given-names>Wataru</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Platform Project for Supporting Drug Discovery and Life Science Research</institution></institution-wrap></funding-source><award-id>JP22ama121002 (support number 3272)</award-id><principal-award-recipient><name><surname>Shihoya</surname><given-names>Wataru</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The cryo-EM structure of ET<sub>B</sub>-G<sub>i</sub> complex, obtained using the Fusion-G system, provides insights into the distinct activation mechanism and G-protein promiscuity of ET<sub>B</sub>, aiding in the design of ET<sub>B</sub> agonists for therapeutic applications.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Endothelins are 21-amino-acid vasoconstricting peptides produced primarily in the endothelium <xref ref-type="bibr" rid="bib56">Yanagisawa et al., 1988</xref> and play a key role in vascular homeostasis. Among the three endothelin isopeptides (ET-1–3), ET-1 was first discovered as a potent vasoconstrictor <xref ref-type="bibr" rid="bib32">Maguire and Davenport, 2014</xref>; <xref ref-type="bibr" rid="bib11">Davenport et al., 2016</xref>. ET-1 transmits signals through two receptor subtypes, the ET<sub>A</sub> and ET<sub>B</sub> receptors, which belong to the class A G-protein-coupled receptors (GPCRs) <xref ref-type="bibr" rid="bib4">Arai et al., 1990</xref>; <xref ref-type="bibr" rid="bib44">Sakurai et al., 1990</xref>. The endothelin receptors exert regulatory control over cellular processes important for growth, survival, invasion, and angiogenesis <xref ref-type="bibr" rid="bib20">Haryono et al., 2022</xref>; <xref ref-type="bibr" rid="bib6">Barton and Yanagisawa, 2019</xref>. In the vascular system, the ET<sub>A</sub> receptor serves as the primary mediator of vasoconstriction, and its irreversible binding to ET-1 leads to prolonged vasoconstriction. By contrast, the ET<sub>B</sub> receptor primarily induces vasorelaxation via the nitric oxide-mediated pathway, and it acts as a clearance receptor that removes circulating ET-1 via the lysosomal pathway <xref ref-type="bibr" rid="bib8">Bremnes et al., 2000</xref>. The ET<sub>B</sub> receptor is known to be a promiscuous GPCR, capable of activating multiple types of G-proteins <xref ref-type="bibr" rid="bib24">Inoue et al., 2019</xref>; <xref ref-type="bibr" rid="bib14">Doi et al., 1999</xref>. In vascular smooth muscle, it induces nitric oxide-mediated vasorelaxation via G<sub>q</sub> signaling. Furthermore, the astrocytic ET<sub>B</sub> receptor-mediated G<sub>i</sub> signal reduces intercellular communication through gap junctions <xref ref-type="bibr" rid="bib49">Tencé et al., 2012</xref>, and the Rho signal in astrocytes leads to cytoskeletal reorganization and cell-adhesion-dependent proliferation <xref ref-type="bibr" rid="bib29">Koyama and Baba, 1996</xref>, promoting the induction of reactive astrocytes and neuroprotection <xref ref-type="bibr" rid="bib30">Koyama, 2021</xref>.</p><p>Drug development targeting the endothelin receptors has primarily focused on antagonists owing to the vasodilation effect <xref ref-type="bibr" rid="bib20">Haryono et al., 2022</xref>; <xref ref-type="bibr" rid="bib6">Barton and Yanagisawa, 2019</xref>. Bosentan, the first non-peptide antagonist for ET<sub>A</sub> and ET<sub>B</sub>, is currently in clinical use for the treatment of pulmonary arterial hypertension. Moreover, ET<sub>A</sub>-selective antagonists are used as therapeutic agents with fewer side effects. Notably, endothelin-1 acts primarily through the ET<sub>A</sub> receptor and is implicated in the neoplastic growth of multiple tumor types. Thus, endothelin receptor antagonists such as atrasentan and zibotentan have demonstrated potential anticancer activity in preclinical studies <xref ref-type="bibr" rid="bib43">Rosanò et al., 2013</xref>. The development of ET<sub>B</sub> agonists is also underway, as they provide therapeutic benefits such as vasodilation and neuroprotection <xref ref-type="bibr" rid="bib11">Davenport et al., 2016</xref>; <xref ref-type="bibr" rid="bib30">Koyama, 2021</xref>. IRL1620, a truncated analog of ET-1, is the smallest ET<sub>B</sub>-selective agonist that has been shown to selectively and transiently increase tumor blood flow <xref ref-type="bibr" rid="bib19">Gulati et al., 2012</xref>, making it a potential adjuvant cancer therapy for enhancing the delivery of anti-tumor drugs and acute ischemic stroke <xref ref-type="bibr" rid="bib40">Ranjan and Gulati, 2022</xref>. However, IRL1620 is a linear peptide with exposed N- and C-termini and thus has problems in terms of pharmacokinetics and drug delivery. Currently, small-molecule ET<sub>B</sub>-selective agonists have not been developed, hindering drug development targeting the ET<sub>B</sub> receptor.</p><p>To date, eight crystal structures of the human ET<sub>B</sub> receptor have been reported, elucidating the structure-activity relationships of the peptide agonists and small-molecule clinical antagonists <xref ref-type="bibr" rid="bib45">Shihoya et al., 2016</xref>; <xref ref-type="bibr" rid="bib34">Nagiri et al., 2019</xref>; <xref ref-type="bibr" rid="bib25">Izume et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Shihoya et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Shihoya et al., 2017</xref>. Nevertheless, the detailed activation mechanism has remained elusive due to the crystallization constructs containing T4 lysozyme in the intracellular loop (ICL) 3 and thermostabilizing mutations <xref ref-type="bibr" rid="bib38">Okuta et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Nakai et al., 2022</xref> that stabilize the inactive state. Moreover, the conserved N<sup>7.49</sup>P<sup>7.50</sup>xxY<sup>7.53</sup> motif (superscripts indicate Ballesteros–Weinstein numbers <xref ref-type="bibr" rid="bib5">Ballesteros and Weinstein, 1995</xref>) essential for G-protein activation <xref ref-type="bibr" rid="bib50">Venkatakrishnan et al., 2013</xref> is altered to N<sup>7.49</sup>P<sup>7.50</sup>xxL<sup>7.53</sup>Y<sup>7.54</sup> in the wild-type ET<sub>B</sub> receptor. Thus, little is known about ET<sub>B</sub>-mediated G-protein activation. Here, we report the 2.8 Å-resolution cryo-electron microscopy (cryo-EM) structure of the human ET<sub>B</sub>-G<sub>i</sub> signaling complex bound to ET-1, revealing the unique mechanisms of receptor activation and G-protein coupling.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Development of fusion-G system for structural determination</title><p>For the cryo-EM analysis, we initially used the thermostabilized receptor ET<sub>B</sub>-Y5, which contains five thermostabilizing mutations <xref ref-type="bibr" rid="bib38">Okuta et al., 2016</xref>. However, the purified ET<sub>B</sub>-Y5 could not form a stable complex with the G<sub>i</sub> trimer because the mutations were known to stabilize the inactive conformation. Thus, we chose to use the wild-type ET<sub>B</sub> for the structural study. To purify the stable GPCR-G-protein complex, we developed a ‘Fusion-G system’ (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) by combining two complex stabilization techniques. One of these techniques was the NanoBiT tethering strategy <xref ref-type="bibr" rid="bib15">Duan et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Dixon et al., 2016</xref>, where the large part of NanoBiT (LgBiT) was fused to the C-terminus of the receptor, and a modified 13-amino acid peptide of NanoBiT (HiBiT) was fused to the C-terminus of Gβ via the GS linker. HiBit has a potent affinity for LgBiT (<italic>Kd =</italic> 700 pM) and thus provides an additional linkage to stabilize the interface between H8 of the receptor and the Gβ subunit of the G-protein. This strategy has been successfully used to solve several GPCR/G-protein complex structures <xref ref-type="bibr" rid="bib15">Duan et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Xia et al., 2021</xref>. The other technique was a 3-in-1 vector for G-protein expression, in which the Gα subunit was fused to the C-terminus of the Gγ subunit (<xref ref-type="bibr" rid="bib27">Kim et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Nureki et al., 2022</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). The resulting pFastBac-Dual vector could produce a virus that expressed the G-protein trimer. Moreover, the protease-cleavable green fluorescent protein (EGFP) was connected to the C-terminus of the receptor-LgBiT fusion, allowing analysis of complex formation by fluorescence-detection size-exclusion chromatography (FSEC) <xref ref-type="bibr" rid="bib21">Hattori et al., 2012</xref>. Using this system, we confirmed the complex formation of LPA<sub>1</sub> and S1P<sub>5</sub> with G<sub>i</sub> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A, B</xref>), whose structures in complex with the G<sub>i</sub> trimer had previously been reported <xref ref-type="bibr" rid="bib3">Akasaka et al., 2022</xref>; <xref ref-type="bibr" rid="bib31">Liu et al., 2022</xref>; <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Xu et al., 2022a</xref>.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Overall structure of the ET-1-ETB-Gi signaling complex.</title><p>(<bold>A</bold>) Schematic representations of the fusion-G system. (<bold>B</bold>) Fluorescence-detection size-exclusion chromatography (FSEC) analysis of complex formation by the ET<sub>B</sub> receptor. The fluorescence intensities are adjusted to equalize those corresponding to the void volumes. (<bold>C</bold>) Cryo-electron microscopy (cryo-EM) map with variously colored densities. (<bold>D</bold>) Structure of the complex determined after refinement in the cryo-EM map, shown as a ribbon representation. (<bold>E</bold>) Density focused on ET-1.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85821-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Fusion-G system.</title><p>(<bold>A, B</bold>) Fluorescence-detection size-exclusion chromatography (FSEC) analysis of the complex formation of LPA<sub>1</sub> (<bold>A</bold>) and S1P<sub>5</sub> (<bold>B</bold>). The fluorescence intensities are adjusted to equalize those corresponding to the void volumes. When co-expressed with the G<sub>i</sub> trimer, the peak corresponding to the complex appears on the high molecular weight side of the receptor, reflecting the basal activity and the HiBiT-LgBiT binding, independent of the G-protein. When the co-expressed cells were treated with the agonists and apyrase, the complex peak of LPA<sub>1</sub> and S1P<sub>5</sub> became larger, corresponding to the GPCR-G-protein complex. (<bold>C</bold>) Size-exclusion chromatography elution profiles of the ET<sub>B</sub> -G<sub>i</sub> complex. (<bold>D</bold>) SDS-PAGE analysis of the gel filtration fractions. Although the unbound receptor was present, the complex could be separated and purified effectively.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>An uncropped image of a gel.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85821-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85821-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Cryo-electron microscopy (Cryo-EM) workflow, maps, and model quality.</title><p>Flow chart of the cryo-EM data processing for the ET<sub>B</sub> -G<sub>i</sub> complex, including particle projection selection, classification, and three-dimensional (3D) density map reconstruction. Local resolution maps, FSC curves, and cryo-EM density maps are also shown. Unless otherwise noted, analysis jobs were run on cryoSPARC v3.3. Details are provided in the Methods section.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85821-fig1-figsupp2-v1.tif"/></fig></fig-group><p>We cloned the full-length human ET<sub>B</sub> receptor into the LgBiT vector. Using the fusion-G-system, we confirmed the formation of the ET<sub>B</sub>-G<sub>i</sub> complex (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The co-expressed cells from a 300 ml culture were solubilized and purified by Flag affinity chromatography. After incubation with scFv16, the complex was purified by size exclusion chromatography (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C, D</xref>). The structure of the purified complex was determined by single-particle cryo-EM analysis with an overall resolution of 2.8  Å (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). No density corresponding to NanoBiT was observed in the 2D class averages and reconstructed 3D density map, as in the previous structural studies using the NanoBiT tethering strategy <xref ref-type="bibr" rid="bib15">Duan et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Xia et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib55">Xu et al., 2022b</xref>. We refined with a mask on the receptor and obtained the receptor structure with a nominal resolution of 3.1  Å (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). The agonist ET-1 is well resolved (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Cryo-EM data collection, refinement, and validation statistics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Data collection</th><th align="left" valign="bottom">ET<sub>B</sub>-G<sub>i</sub> (overall)</th><th align="left" valign="bottom">ET<sub>B</sub>-G<sub>i</sub> (receptor focused)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Microscope</td><td align="left" valign="bottom" colspan="2">Titan Krios (Thermo Fisher Scientific)</td></tr><tr><td align="left" valign="bottom">Voltage (keV)</td><td align="left" valign="bottom" colspan="2">300</td></tr><tr><td align="left" valign="bottom">Electron exposure (e<sup>-</sup>/Å2)</td><td align="left" valign="bottom" colspan="2">49.965</td></tr><tr><td align="left" valign="bottom">Detector</td><td align="left" valign="bottom" colspan="2">Gatan K3 summit camera (Gatan)</td></tr><tr><td align="left" valign="bottom">Magnification</td><td align="left" valign="bottom" colspan="2">×105,000</td></tr><tr><td align="left" valign="bottom">Defocus range (μm)</td><td align="left" valign="bottom" colspan="2">–0.8–1.6</td></tr><tr><td align="left" valign="bottom">Pixel size (Å/pix)</td><td align="left" valign="bottom" colspan="2">0.83</td></tr><tr><td align="left" valign="bottom">Number of movies</td><td align="left" valign="bottom" colspan="2">10,408</td></tr><tr><td align="left" valign="bottom">Symmetry</td><td align="left" valign="bottom" colspan="2">C1</td></tr><tr><td align="left" valign="bottom">Picked particles</td><td align="left" valign="bottom" colspan="2">3,863,134</td></tr><tr><td align="left" valign="bottom">Final particles</td><td align="left" valign="bottom" colspan="2">260,085</td></tr><tr><td align="left" valign="bottom">Map resolution (Å)</td><td align="left" valign="bottom">2.80</td><td align="char" char="." valign="bottom">3.13</td></tr><tr><td align="left" valign="bottom">FSC threshold</td><td align="left" valign="bottom" colspan="2">0.143</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Model refinement</bold></td></tr><tr><td align="left" valign="bottom">Atoms</td><td align="left" valign="bottom">9,367</td><td align="char" char="." valign="bottom">2,523</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>R.m.s. deviations for ideal</bold></td></tr><tr><td align="left" valign="bottom">Bond lengths (Å)</td><td align="left" valign="bottom">0.002</td><td align="char" char="." valign="bottom">0.003</td></tr><tr><td align="left" valign="bottom">Bond angles (°)</td><td align="left" valign="bottom">0.56</td><td align="char" char="." valign="bottom">0.52</td></tr><tr><td align="left" valign="bottom">Validation</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Clashscore</td><td align="left" valign="bottom">11.68</td><td align="char" char="." valign="bottom">7.7</td></tr><tr><td align="left" valign="bottom">Rotamers (%)</td><td align="left" valign="bottom">0.00</td><td align="char" char="." valign="bottom">0.00</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Ramachandran plot</bold> </td></tr><tr><td align="left" valign="bottom">Favored (%)</td><td align="left" valign="bottom">96.55</td><td align="char" char="." valign="bottom">98.04</td></tr><tr><td align="left" valign="bottom">Allowed (%)</td><td align="left" valign="bottom">3.19</td><td align="char" char="." valign="bottom">1.96</td></tr><tr><td align="left" valign="bottom">Outlier (%)</td><td align="left" valign="bottom">0.26</td><td align="char" char="." valign="bottom">0.00</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>Receptor conformational changes upon G<sub>i</sub> activation</title><p>The extracellular half of the receptor superimposes well on the ET-1-bound crystal structure, and ET-1 interacts closely with the receptor in a similar manner (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Previous crystallographic analyses have suggested that the ET-1 binding leads to the downward movement of N378<sup>7.45</sup> and W336<sup>6.48</sup> in the C<sup>6.47</sup>W<sup>6.48</sup>xP<sup>6.50</sup> motif at the bottom of the ligand binding pocket, which ultimately results in the downward rotation of F332<sup>6.44</sup> in the P<sup>5.50</sup>I<sup>3.40</sup>F<sup>6.44</sup> motif, and leading to the intracellular opening <xref ref-type="bibr" rid="bib45">Shihoya et al., 2016</xref>; <xref ref-type="bibr" rid="bib34">Nagiri et al., 2019</xref>; <xref ref-type="bibr" rid="bib25">Izume et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Shihoya et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Shihoya et al., 2017</xref>. The downward movement of the residues is larger in the ET<sub>B</sub>-G<sub>i</sub> complex than in the ET-1-bound crystal structure (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), which consequently results in the outward displacement of the intracellular portion of the transmembrane helix (TM) 6 by 6.8 Å as compared to the apo state (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), and by 5.1 Å as compared to the ET-1-bound crystal structure (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The degree of TM6 opening observed is less than those of other G<sub>i</sub>-coupled receptors (e.g. μOR: 10 Å, CB<sub>1</sub>: 11.6 Å, and S1P<sub>1</sub>: 9 Å) <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Zhuang et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Hua et al., 2020</xref>.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Structural changes upon G-protein activation.</title><p>(<bold>A</bold>) Superimposition of the ET-1-bound receptor in the crystal and cryo-electron microscopy (cryo-EM) structures. (<bold>B</bold>) Superimposition of the ET<sub>B</sub> structures, focused on the receptor core. (<bold>C, D</bold>) Superimpositions of the G<sub>i</sub>-complexed ET<sub>B</sub> structure with the ET-1-bound crystal structure (<bold>C</bold>) and apo structure (<bold>D</bold>). (<bold>E-G</bold>) D<sup>3.49</sup>R<sup>3.50</sup>Y<sup>3.51</sup> and N<sup>7.49</sup>P<sup>7.50</sup>xxY<sup>7.53</sup> motifs in ET<sub>B</sub> (<bold>E</bold>), β2AR (<bold>F</bold>), and μOR (<bold>G</bold>). Black dashed lines indicate hydrogen bonds.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85821-fig2-v1.tif"/></fig><p>In most class A GPCRs, the highly conserved D<sup>3.49</sup>R<sup>3.50</sup>Y<sup>3.51</sup> and N<sup>7.49</sup>P<sup>7.50</sup>xxY<sup>7.53</sup> motifs on the intracellular side play an essential role in G-protein coupling <xref ref-type="bibr" rid="bib50">Venkatakrishnan et al., 2013</xref>. The D<sup>3.49</sup>R<sup>3.50</sup>Y<sup>3.51</sup> motif is conserved in the ET<sub>B</sub> receptor. Upon receptor activation, the ionic lock between D198<sup>3.49</sup> and R199<sup>3.50</sup> is broken, and R199<sup>3.50</sup> becomes oriented towards the intracellular cavity (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), similar to other GPCRs <xref ref-type="bibr" rid="bib58">Zhuang et al., 2022</xref>; <xref ref-type="bibr" rid="bib41">Rasmussen et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">Ring et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Cherezov et al., 2007</xref>; <xref ref-type="bibr" rid="bib33">Manglik et al., 2012</xref>; <xref ref-type="bibr" rid="bib23">Huang et al., 2015</xref> (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref>). In contrast, the N<sup>7.49</sup>P<sup>7.50</sup>xxY<sup>7.53</sup> motif is altered to N<sup>7.49</sup>P<sup>7.50</sup>xxL<sup>7.53</sup>Y<sup>7.54</sup>, where Y<sup>7.53</sup> is replaced by L386<sup>7.53</sup>. In most class A GPCRs, receptor activation disrupts the stacking interaction between Y<sup>7.53</sup> and F<sup>8.50</sup> <xref ref-type="bibr" rid="bib9">Carpenter and Tate, 2017</xref>. Y<sup>7.53</sup> moves inwardly and forms a water-mediated hydrogen bond with the highly conserved Y<sup>5.58</sup> (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref>; <xref ref-type="bibr" rid="bib42">Ring et al., 2013</xref>; <xref ref-type="bibr" rid="bib23">Huang et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Deupi et al., 2012</xref>). The mutations of the tyrosines significantly reduce G-protein activation <xref ref-type="bibr" rid="bib18">Goncalves et al., 2010</xref>; <xref ref-type="bibr" rid="bib17">Flock et al., 2015</xref>, indicating that the interaction between Y<sup>5.58</sup>-and Y<sup>7.53</sup> stabilizes the active conformation of the receptor. Along with the motion, the intracellular portion of TM7 is displaced by approximately 4 Å. As L386<sup>7.53</sup> is a hydrophobic residue, it cannot form a polar interaction, and hence in the ET<sub>B</sub>-G<sub>i</sub> complex, TM7 is not displaced inwardly (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Nonetheless, the stacking interaction with F393<sup>8.50</sup> is disrupted similarly. Moreover, the intracellular portion of TM7 is displaced downward by 2.8 Å. As expected, Y<sup>7.54</sup> is directed towards the membrane plane, and its rotamer does not change upon receptor activation (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). The substitution of Y<sup>7.53</sup> with L386<sup>7.53</sup> affects the movement of TM7 upon receptor activation, thereby distinguishing it from other GPCRs.</p></sec><sec id="s2-3"><title>Shallow G<sub>i</sub> coupling</title><p>These conformational changes create an intracellular cavity for G-protein recognition (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). The cavity closely interacts with the C-terminal α5-helix of Gα<sub>i</sub>, the primary determinant for G-protein coupling. In particular, R199<sup>3.50</sup> forms a hydrogen bond with the backbone carbonyl of C351<sup>G.H5.23</sup> (superscript indicates the common Gα numbering [CGN] system <xref ref-type="bibr" rid="bib17">Flock et al., 2015</xref>), which is commonly observed in other GPCR-G<sub>i</sub> complexes <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Zhuang et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Hua et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Kato et al., 2019</xref>. Additionally, the C-terminal carboxylate of α5-helix forms electrostatic interactions with the backbone nitrogen atom of K391<sup>8.48</sup>. There are several other hydrogen-bonding interactions between the α5-helix and the receptor (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). On ICL2, W206<sup>ICL2</sup> fits into a hydrophobic pocket formed by L194<sup>G.S3.01</sup>, F336<sup>G.H5.08</sup>, T340<sup>G.H5.12</sup>, I343<sup>G.H5.15</sup>, and I344<sup>G.H5.16</sup> in the Gα<sub>i</sub> subunit. Moreover, ICL2 forms extensive van der Waals interactions with the αN (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), which are not observed in other GPCR-G<sub>i</sub> complexes (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Hua et al., 2020</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Comparison of the Gi binding modes.</title><p>(<bold>A</bold>) Hydrogen-bonding interactions between ET<sub>B</sub> and the α5-helix, indicated by black dashed lines. (<bold>B</bold>) Comparison of the Gα positions in the GPCR-G-protein complexes. The structures are superimposed on the receptor structure of the NTS<sub>1</sub>-C state.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85821-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Detailed ET<sub>B</sub>-G<sub>i</sub> interface.</title><p>(<bold>A, B</bold>) Receptor-G<sub>i</sub> interactions within 4.5 Å. Black dashed lines indicate hydrogen bonds. (<bold>C-E</bold>) Structural comparisons of the interactions between ICL2 and G<sub>i</sub> in ET<sub>B</sub> (<bold>C</bold>), S1P<sub>1</sub> (<bold>D</bold>), and CB<sub>1</sub> (<bold>E</bold>). Residues are shown as stick and CPK models. (<bold>F</bold>) Structural comparison of the Gα<sub>i1</sub> subunits.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85821-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Comparison of the interactions between the α5-helix and TM7-H8.</title><p>(<bold>A-F</bold>) Interactions between the α5-helix and TM7-H8 within 4.5 Å in the respective complexes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85821-fig3-figsupp2-v1.tif"/></fig></fig-group><p>Upon receptor activation, the intracellular portion of TM7 moves downwards, resulting in the unique G<sub>i</sub> coupling mode. Along with this motion, L386<sup>7.53</sup> directly forms a hydrophobic contact with G352<sup>G.H5.24</sup>. Moreover, TM7 and H8 extensively interact with the α5-helix (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>), which is not observed in other GPCR-G<sub>i</sub> complexes (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>; <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Zhuang et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Hua et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Kato et al., 2019</xref>). These structural features enable the α5-helix of ET<sub>B</sub>-G<sub>i</sub> to be located in the shallowest position relative to the receptor among the G<sub>s</sub>, G<sub>i</sub>, and G<sub>q</sub>-coupled GPCR structures (<xref ref-type="bibr" rid="bib27">Kim et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Zhuang et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Hua et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Rasmussen et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Kato et al., 2019</xref>; <xref ref-type="fig" rid="fig3">Figure 3B</xref>). Nevertheless, the Gα<sub>i</sub> structure adopts a nucleic acid-free state, similar to the μOR-G<sub>i</sub> complex (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib58">Zhuang et al., 2022</xref>; <xref ref-type="bibr" rid="bib51">Wall et al., 1995</xref>). The interacting surface area between the receptor and Gα<sub>i</sub> subunit is 1,196 Å<sup>2</sup>, which is comparable to those in other GPCR-G<sub>i</sub> complexes (µOR : 1,260 Å<sup>2</sup>. NTS<sub>1</sub> : 1,197 Å<sup>2</sup>. and S1P<sub>1</sub>: 1,376 Å<sup>2</sup>. <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Zhuang et al., 2022</xref>; <xref ref-type="bibr" rid="bib26">Kato et al., 2019</xref>). As described above, ICL2 and TM7 extensively interact with the αN and α5 helix of the Gα<sub>i</sub> subunit, respectively. These interactions are uniquely observed in the ET<sub>B</sub>-G<sub>i</sub> complex and can compensate for the shallow binding of G<sub>i</sub>.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we established the Fusion-G system, which facilitates the efficient expression and purification of the GPCR-G-protein complex. Additionally, the ability to monitor the fluorescence of GFP fused in the C-terminus of the receptor makes it easier to optimize the expression and purification conditions. The tethering strategy only increases the proportion of the complex by constantly placing the G-protein around the receptor rather than tightly anchoring the complex, suggesting that the fusion-G-system has minimal effect on the complex structure. It should be noted that the potential artifacts resulting from the tethering strategy cannot be entirely ruled out. The hybrid approach we have developed, combining NanoBiT tethering and FSEC methodology, is an effective option for comprehensive structural analysis of various other membrane protein complexes.</p><p>The ET<sub>B</sub>-G<sub>i</sub> structure determined by this strategy filled in the last piece of the puzzle, and our understanding of the mechanism of receptor activation has been significantly deepened. The ligand binding pocket is essentially similar in both the crystal structure of the receptor alone and in the G<sub>i</sub> protein complex (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). However, the W336<sup>6.48</sup> rotamer, which comprises the bottom of the ligand-binding pocket, differs (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), thereby leading to the activation of the intracellular side of the receptor (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). Thus, it may be crucial to choose and evaluate compounds based on the bottom of the ligand pocket in the current ET<sub>B</sub>-G<sub>i</sub> structure (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) to develop small molecule ET<sub>B</sub> agonists for neuroprotection and cancer therapy.</p><p>Previous structural analyses have demonstrated that docking the α5-helix to the receptor cavity leads to destabilization of the nucleic acid binding site located at the root of the α5-helix (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib58">Zhuang et al., 2022</xref>; <xref ref-type="bibr" rid="bib41">Rasmussen et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Su et al., 2020</xref>), thus promoting the GDP/GTP exchange reaction. While the binding of Gα<sub>s</sub> remains mostly indistinguishable in all complexes, the binding of Gα<sub>i</sub> varies, displaying different Gα rotations in relation to the receptor <xref ref-type="bibr" rid="bib37">Okamoto et al., 2021</xref>. Nevertheless, the depth of the docking towards the receptor remains constant (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Since the N<sup>7.49</sup>P<sup>7.50</sup>xxY<sup>7.53</sup> motif is not conserved in ET<sub>B</sub>, TM7 undergoes the downward movement upon the G<sub>i</sub> binding, resulting in the shallow position of the α5-helix. Thus, the restrictions of the residues in the α5-helix may be less strict, accounting for the G-protein promiscuity of ET<sub>B</sub>. Since the other promiscuous GPCRs (e.g. NTS<sub>1</sub>) preserve the N<sup>7.49</sup>P<sup>7.50</sup>xxY<sup>7.53</sup> motif, the proposed mechanism for G-protein promiscuity may be unique to ET<sub>B</sub>. Such information is essential for understanding the mechanism of G-protein activation by GPCRs.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">peptide, recombinant protein</td><td align="left" valign="bottom">ET-1</td><td align="left" valign="bottom">PEPTIDE INSTITUTE, INC.</td><td align="left" valign="bottom">Cat #,<break/>4198 v</td><td align="left" valign="bottom">Ligand for ET<sub>B</sub></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Sf-900 II SFM</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #,<break/>10902088</td><td align="left" valign="bottom">Expression medium for sf9 cells</td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">n-dodecyl-β-D-maltoside</td><td align="left" valign="bottom">Calbiochem</td><td align="left" valign="bottom">CAS number:<break/>69227-93-6</td><td align="left" valign="bottom">Detergents used in purification of ET<sub>B</sub>-G<sub>i</sub> complex</td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Cholesteryl hemisuccinate</td><td align="left" valign="bottom">Merck Millipore</td><td align="left" valign="bottom">CAS number:<break/>1510-21-0</td><td align="left" valign="bottom">For purifying ET<sub>B</sub>-G<sub>i</sub> complex</td></tr><tr><td align="left" valign="bottom">peptide, recombinant protein</td><td align="left" valign="bottom">Apyrase</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat #,<break/>M0398</td><td align="left" valign="bottom">Enzyme used for ET<sub>B</sub>-G<sub>i</sub> complex formation</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Anti-DYKDDDDK G1 Affinity resin</td><td align="left" valign="bottom">Gen Script</td><td align="left" valign="bottom">Cat #,<break/>L00432</td><td align="left" valign="bottom">Affinity resin for DYKDDDDK tags</td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Lauryl Maltose Neopentyl Glycol</td><td align="left" valign="bottom">Anatrace</td><td align="left" valign="bottom">CAS number:<break/>1257852-96-2</td><td align="left" valign="bottom">Detergents used in purification of ET<sub>B</sub>-G<sub>i</sub> complex</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">EPU</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom"/><td align="left" valign="bottom">For Cryo-EM data collection</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">RELION-3.1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib59">Zivanov et al., 2018</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016274">SCR_016274</ext-link></td><td align="left" valign="bottom">For Cryo-EM data processing</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">cryoSPARC v3.3</td><td align="left" valign="bottom">STRUCTURA BIOTECHNOLOGY</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016501">SCR_016501</ext-link></td><td align="left" valign="bottom">For cryo-EM data processing</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Coot</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib16">Emsley et al., 2010</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014222">SCR_014222</ext-link></td><td align="left" valign="bottom">For structure model building</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Phenix 1.19–4092</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Afonine et al., 2018</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014224">SCR_014224</ext-link></td><td align="left" valign="bottom">For structure refinement</td></tr><tr><td align="left" valign="bottom">other</td><td align="left" valign="bottom">Quantifoil holey carbon grid</td><td align="left" valign="bottom">Quantifoil</td><td align="left" valign="bottom">R1.2/1.3, Au, 300 mesh</td><td align="left" valign="bottom">For cryo-EM specimen preparation</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Constructs</title><p>The full-length human ET<sub>B</sub> gene was subcloned into the pFastBac vector with an HA-signal peptide sequence on its N-terminus and the LgBiT fused to its C-terminus followed by a 3 C protease site and EGFP-His8 tag. A 15 amino sequence of GGSGGGGSGGSSSGG was inserted into both the N-terminal and C-terminal sides of LgBiT. The Flag epitope tag (DYKDDDDK) was introduced between G57 and L66. The native signal peptide was replaced with the haemagglutinin signal peptide. Rat Gβ<sub>1</sub> and bovine Gγ<sub>2</sub> were subcloned into the pFastBac Dual vector, as described previously <xref ref-type="bibr" rid="bib28">Kobayashi et al., 2020</xref>. In detail, rat Gβ<sub>1</sub> was cloned with a C-terminal HiBiT connected with a 15 amino sequence of GGSGGGGSGGSSSGG. Moreover, human Gα<sub>i1</sub> was subcloned into the C-terminus of the bovine Gγ<sub>2</sub> with a nine amino sequence GSAGSAGSA linker. The resulting pFastBac dual vector can express the G<sub>i</sub> trimer.</p></sec><sec id="s4-2"><title>Complex formation and FSEC analysis</title><p>Bacmid preparation and virus production was performed according to the Bac-to-Bac baculovirus system manual (Gibco, Invitrogen). <italic>Spodoptera frugiperda</italic> Sf9 cells at a density of 3 × 10<sup>6</sup> cells/ml were co-infected with baculoviruses encoding receptor and G<sub>i</sub> trimer at the ratio of 1:1. For the expression of the receptor alone, the baculovirus encoding receptor was only used. Cells were harvested 48  hr after infection. 1 ml cell pellets were solubilized in 200 μl buffer, containing 20  mM Tris-HCl, pH 8.0, 150  mM NaCl, 1% n-dodecyl-β-D-maltoside (DDM) (Calbiochem), 0.2% cholesteryl hemisuccinate (CHS) (Merck) and rotated for 1  hr at 4 °C.</p><p>For the complex formation with the agonist, cell pellets were resuspended in 20  mM Tris-HCl, pH 8.0, 100  mM NaCl, and 10% Glycerol, and homogenized by douncing ~20 times. Apyrase was added to the lysis at a final concentration of 25 mU/ml. Each agonist was added at a final concentration of 10  µM. The homogenate was incubated at room temperature for 1  hr with flipping. Then, DDM and CHS were added to a final concentration of 1% and 0.2%, respectively for 1  hr at 4 °C.</p><p>The supernatants were separated from the insoluble material by ultracentrifugation at 100,000 g for 20  min. A fraction of the resulting supernatant (10 μl) was loaded onto a Superdex 200 increase 10/300 column in 20  mM Tris-HCl, pH 8.0, 150  mM NaCl, and 0.03% DDM, and run at the flow rate of 0.5 ml/min. The eluent was detected by a fluorometer with the excitation wavelength (480 nm) and emission wavelength settings (512 nm).</p></sec><sec id="s4-3"><title>ET-1–ET<sub>B</sub>–G<sub>i</sub> complex formation and purification</title><p>For expression, 300 ml of the Sf9 cells at a density of 3 × 10<sup>6</sup> cells/ml were co-infected with baculovirus encoding the ET<sub>B</sub>-LgBiT-EGFP and G<sub>i</sub> trimer at the ratio of 1:1. Cells were harvested 48  hr after infection. Cell pellets were resuspended in 20  mM Tris-HCl, pH 8.0, 100  mM NaCl, and 10% Glycerol, and homogenized by douncing ~30 times. Apyrase was added to the lysis at a final concentration of 25 mU/ml. ET-1 was added at a final concentration of 2  µM. The lysate was incubated at room temperature for 1  hr with flipping. Then, the membrane fraction was collected by ultracentrifugation at 180,000 g for 1 hr. The cell membrane was solubilized in buffer, containing 20  mM Tris-HCl, pH 8.0, 150  mM NaCl, 1% DDM, 0.2% CHS, 10% glycerol, and 2 μM ET-1 for 1  hr at 4 °C. The supernatant was separated from the insoluble material by ultracentrifugation at 180,000 g for 30  min and then incubated with the Anti-DYKDDDDK G1 resin (Genscript) for 1 hr. The resin was washed with 20 column volumes of wash buffer containing 20  mM Tris-HCl, pH 8.0, 500  mM NaCl, 10% Glycerol, 0.1% Lauryl Maltose Neopentyl Glycol (LMNG) (Anatrace), and 0.01% CHS. The complex was eluted by the wash buffer containing 0.15 mg ml<sup>–1</sup> Flag peptide. The eluate was treated with 0.5 mg of HRV-3C protease (homemade) and dialyzed against buffer (20  mM Tris-HCl, pH 8.0, and 300  mM NaCl). Then, cleavaged GFP-His<sub>8</sub> and HRV-3C protease were removed with Ni<sup>+</sup>-NTA resin. The flow-through was incubated with the scFv16, prepared as described previously <xref ref-type="bibr" rid="bib37">Okamoto et al., 2021</xref>. The complex was concentrated and loaded onto a Superdex 200 increase 10/300 column in 20  mM Tris-HCl, pH 8.0, 150  mM NaCl, 0.01% LMNG, 0.001% CHS, and 1 μM agonist. Peak fractions were concentrated to 8 mg/ml.</p></sec><sec id="s4-4"><title>Cryo-EM grid preparation and data acquisition</title><p>The purified complex was applied onto a freshly glow-discharged Quantifoil holey carbon grid (R1.2/1.3, Au, 300 mesh) and plunge-frozen in liquid ethane by using a Vitrobot Mark IV (FEI). Cryo-EM data collection was performed on a 300 kV Titan Krios G3i microscope (Thermo Fisher Scientific) equipped with a BioQuantum K3 imaging filter (Gatan) and a K3 direct electron detector (Gatan). In total, 10,408 movies were acquired with a calibrated pixel size of 0.83  Å pix−1 and with a defocus range of −0.8 to −1.6  μm, using the EPU software (Thermo Fisher’s single-particle data collection software). Each movie was acquired for 2.3  s and split into 48 frames, resulting in an accumulated exposure of about 49.965 e− Å−2.</p><p>All acquired movies in super-resolution mode were binned by 2x and were dose-fractionated and subjected to beam-induced motion correction implemented in RELION 3.1 <xref ref-type="bibr" rid="bib59">Zivanov et al., 2018</xref>. The contrast transfer function (CTF) parameters were estimated using patch CTF estimation in cryoSPARC v3.3 <xref ref-type="bibr" rid="bib39">Punjani et al., 2017</xref>. Particles were initially picked from a small fraction with the Blob picker and subjected to several rounds of two-dimensional (2D) classification in cryoSPARC. Selected particles were used for training of topaz model <xref ref-type="bibr" rid="bib7">Bepler et al., 2019</xref>. For the full dataset, 3,863,134 particles were picked and extracted with a pixel size of 3.32 Å, followed by 2D classification to remove carbon edges and ice contaminations. A total of 1,442,243 particles were re-extracted with the pixel size of 1.16 Å and curated by three-dimensional (3D) classification without alignment in RELION. Finally, the 260,085 particles in the best class were reconstructed using non-uniform refinement, resulting in a 2.80 Å overall resolution reconstruction, with the gold standard Fourier Shell Correlation (FSC = 0.143) criteria in cryoSPARC. Moreover, the 3D model was refined with a mask on the receptor. As a result, the local resolution of the receptor portion improved with a nominal resolution of 3.13  Å. The local resolution was estimated by cryoSPARC. The processing strategy is described in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p></sec><sec id="s4-5"><title>Model building and refinement</title><p>The quality of the density map was sufficient to build an atomic model. Previously reported high-resolution crystal structure of the ET-3 bound ET<sub>B</sub> receptor (PDB 6IGK) and cryo-EM MT<sub>1</sub>-G<sub>i</sub> structure (PDB 7DB6) were used as the initial models for the model building of receptor and G<sub>i</sub> portions, respectively <xref ref-type="bibr" rid="bib47">Shihoya et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Okamoto et al., 2021</xref>. Initially, the models were fitted into the density map by jiggle fit using COOT <xref ref-type="bibr" rid="bib16">Emsley et al., 2010</xref>. Then, atomic models were readjusted into the density map using COOT and refined using phenix.real_space_refine (v1.19) with the secondary structure restraints using phenix.secondary_structure_restraints <xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>; <xref ref-type="bibr" rid="bib2">Afonine et al., 2018</xref>.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>is a co-founder and scientific advisor for Curreio</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Software, Formal analysis, Validation, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Validation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Resources, Supervision, Funding acquisition, Validation, Methodology, Writing – original draft, Project administration</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-85821-transrepform1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Cryo-EM Density maps and structure coordinates have been deposited in the Electron Microscopy Data Bank (EMDB) and the Protein Data Bank (PDB), with accession codes EMD-35814 and PDB 8IY5 for the ET<sub>B</sub>-G<sub>i</sub> complex, and EMD-35815 and PDB 8IY6 for the ET<sub>B</sub>-G<sub>i</sub> complex (Receptor focused).</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>FK</given-names></name><name><surname>Akasaka</surname><given-names>H</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>ETB-Gi complex bound to Endotheline-1, focused on receptor</data-title><source>Electron Microscopy Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/emdb/EMD-35815">EMD-35815</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>FK</given-names></name><name><surname>Akasaka</surname><given-names>H</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>ETB-Gi complex bound to endothelin-1</data-title><source>Electron Microscopy Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/emdb/EMD-35814">EMD-35814</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>FK</given-names></name><name><surname>Akasaka</surname><given-names>H</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>ETB-Gi complex bound to Endotheline-1, focused on receptor</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/8IY6">8IY6</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset4"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>FK</given-names></name><name><surname>Akasaka</surname><given-names>H</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>ETB-Gi complex bound to endothelin-1</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/8IY5">8IY5</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank K Ogomori and C Harada for their technical assistance. This work was supported by JSPS KAKENHI grants 21H05037 (ON), 22K19371 and 22H02751 (WS); ONO Medical Research Foundation (WS); The Kao Foundation for Arts and Sciences (WS); The Takeda Science Foundation (WS); The Uehara Memorial Foundation (WS); the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED, under grant numbers JP22ama121012 and JP22ama121002 (support number 3272).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Davis</surname><given-names>IW</given-names></name><name><surname>Echols</surname><given-names>N</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Hung</surname><given-names>L-W</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Oeffner</surname><given-names>R</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Zwart</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PHENIX: a comprehensive python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Poon</surname><given-names>BK</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Sobolev</surname><given-names>OV</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Urzhumtsev</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Real-Space refinement in PHENIX for cryo-EM and crystallography</article-title><source>Acta Crystallographica. Section D, Structural Biology</source><volume>74</volume><fpage>531</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1107/S2059798318006551</pub-id><pub-id pub-id-type="pmid">29872004</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akasaka</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Sano</surname><given-names>FK</given-names></name><name><surname>Matsuzaki</surname><given-names>Y</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structure of the active Gi-coupled human lysophosphatidic acid receptor 1 complexed with a potent agonist</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>5417</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-33121-2</pub-id><pub-id pub-id-type="pmid">36109516</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Hori</surname><given-names>S</given-names></name><name><surname>Aramori</surname><given-names>I</given-names></name><name><surname>Ohkubo</surname><given-names>H</given-names></name><name><surname>Nakanishi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Cloning and expression of a cDNA encoding an endothelin receptor</article-title><source>Nature</source><volume>348</volume><fpage>730</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1038/348730a0</pub-id><pub-id pub-id-type="pmid">2175396</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballesteros</surname><given-names>JA</given-names></name><name><surname>Weinstein</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors</article-title><source>Methods in Neurosciences</source><volume>25</volume><fpage>366</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1016/S1043-9471(05)80049-7</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>M</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Endothelin: 30 years from discovery to therapy</article-title><source>Hypertension</source><volume>74</volume><fpage>1232</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.119.12105</pub-id><pub-id pub-id-type="pmid">31679425</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bepler</surname><given-names>T</given-names></name><name><surname>Morin</surname><given-names>A</given-names></name><name><surname>Rapp</surname><given-names>M</given-names></name><name><surname>Brasch</surname><given-names>J</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Noble</surname><given-names>AJ</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Positive-unlabeled convolutional neural networks for particle Picking in cryo-electron micrographs</article-title><source>Nature Methods</source><volume>16</volume><fpage>1153</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0575-8</pub-id><pub-id pub-id-type="pmid">31591578</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bremnes</surname><given-names>T</given-names></name><name><surname>Paasche</surname><given-names>JD</given-names></name><name><surname>Mehlum</surname><given-names>A</given-names></name><name><surname>Sandberg</surname><given-names>C</given-names></name><name><surname>Bremnes</surname><given-names>B</given-names></name><name><surname>Attramadal</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Regulation and intracellular trafficking pathways of the endothelin receptors</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>17596</fpage><lpage>17604</lpage><pub-id pub-id-type="doi">10.1074/jbc.M000142200</pub-id><pub-id pub-id-type="pmid">10747877</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>B</given-names></name><name><surname>Tate</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Active state structures of G protein-coupled receptors highlight the similarities and differences in the G protein and arrestin coupling interfaces</article-title><source>Current Opinion in Structural Biology</source><volume>45</volume><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2017.04.010</pub-id><pub-id pub-id-type="pmid">28482214</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherezov</surname><given-names>V</given-names></name><name><surname>Rosenbaum</surname><given-names>DM</given-names></name><name><surname>Hanson</surname><given-names>MA</given-names></name><name><surname>Rasmussen</surname><given-names>SGF</given-names></name><name><surname>Thian</surname><given-names>FS</given-names></name><name><surname>Kobilka</surname><given-names>TS</given-names></name><name><surname>Choi</surname><given-names>H-J</given-names></name><name><surname>Kuhn</surname><given-names>P</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name><name><surname>Stevens</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>High-Resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor</article-title><source>Science</source><volume>318</volume><fpage>1258</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1126/science.1150577</pub-id><pub-id pub-id-type="pmid">17962520</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>AP</given-names></name><name><surname>Hyndman</surname><given-names>KA</given-names></name><name><surname>Dhaun</surname><given-names>N</given-names></name><name><surname>Southan</surname><given-names>C</given-names></name><name><surname>Kohan</surname><given-names>DE</given-names></name><name><surname>Pollock</surname><given-names>JS</given-names></name><name><surname>Pollock</surname><given-names>DM</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name><name><surname>Maguire</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endothelin</article-title><source>Pharmacological Reviews</source><volume>68</volume><fpage>357</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1124/pr.115.011833</pub-id><pub-id pub-id-type="pmid">26956245</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deupi</surname><given-names>X</given-names></name><name><surname>Edwards</surname><given-names>P</given-names></name><name><surname>Singhal</surname><given-names>A</given-names></name><name><surname>Nickle</surname><given-names>B</given-names></name><name><surname>Oprian</surname><given-names>D</given-names></name><name><surname>Schertler</surname><given-names>G</given-names></name><name><surname>Standfuss</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Stabilized G protein binding site in the structure of constitutively active metarhodopsin-II</article-title><source>PNAS</source><volume>109</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1073/pnas.1114089108</pub-id><pub-id pub-id-type="pmid">22198838</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>AS</given-names></name><name><surname>Schwinn</surname><given-names>MK</given-names></name><name><surname>Hall</surname><given-names>MP</given-names></name><name><surname>Zimmerman</surname><given-names>K</given-names></name><name><surname>Otto</surname><given-names>P</given-names></name><name><surname>Lubben</surname><given-names>TH</given-names></name><name><surname>Butler</surname><given-names>BL</given-names></name><name><surname>Binkowski</surname><given-names>BF</given-names></name><name><surname>Machleidt</surname><given-names>T</given-names></name><name><surname>Kirkland</surname><given-names>TA</given-names></name><name><surname>Wood</surname><given-names>MG</given-names></name><name><surname>Eggers</surname><given-names>CT</given-names></name><name><surname>Encell</surname><given-names>LP</given-names></name><name><surname>Wood</surname><given-names>KV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Nanoluc complementation reporter optimized for accurate measurement of protein interactions in cells</article-title><source>ACS Chemical Biology</source><volume>11</volume><fpage>400</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1021/acschembio.5b00753</pub-id><pub-id pub-id-type="pmid">26569370</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>H</given-names></name><name><surname>Arimoto</surname><given-names>I</given-names></name><name><surname>Hiroaki</surname><given-names>Y</given-names></name><name><surname>Fujiyoshi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Interactions of endothelin receptor subtypes A and B with Gi, go, and Gq in reconstituted phospholipid vesicles</article-title><source>Biochemistry</source><volume>38</volume><fpage>3090</fpage><lpage>3099</lpage><pub-id pub-id-type="doi">10.1021/bi981919m</pub-id><pub-id pub-id-type="pmid">10074362</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>D-D</given-names></name><name><surname>Zhou</surname><given-names>XE</given-names></name><name><surname>Bi</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Q-F</given-names></name><name><surname>Tan</surname><given-names>Y-X</given-names></name><name><surname>Zhuang</surname><given-names>Y-W</given-names></name><name><surname>Zhang</surname><given-names>H-B</given-names></name><name><surname>Xu</surname><given-names>P-Y</given-names></name><name><surname>Huang</surname><given-names>S-J</given-names></name><name><surname>Ma</surname><given-names>S-S</given-names></name><name><surname>He</surname><given-names>X-H</given-names></name><name><surname>Melcher</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-Em structure of an activated VIP1 receptor-G protein complex revealed by a nanobit tethering strategy</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4121</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17933-8</pub-id><pub-id pub-id-type="pmid">32807782</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of coot</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flock</surname><given-names>T</given-names></name><name><surname>Ravarani</surname><given-names>CNJ</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Venkatakrishnan</surname><given-names>AJ</given-names></name><name><surname>Kayikci</surname><given-names>M</given-names></name><name><surname>Tate</surname><given-names>CG</given-names></name><name><surname>Veprintsev</surname><given-names>DB</given-names></name><name><surname>Babu</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Universal allosteric mechanism for Gα activation by GPCRs</article-title><source>Nature</source><volume>524</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1038/nature14663</pub-id><pub-id pub-id-type="pmid">26147082</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goncalves</surname><given-names>JA</given-names></name><name><surname>South</surname><given-names>K</given-names></name><name><surname>Ahuja</surname><given-names>S</given-names></name><name><surname>Zaitseva</surname><given-names>E</given-names></name><name><surname>Opefi</surname><given-names>CA</given-names></name><name><surname>Eilers</surname><given-names>M</given-names></name><name><surname>Vogel</surname><given-names>R</given-names></name><name><surname>Reeves</surname><given-names>PJ</given-names></name><name><surname>Smith</surname><given-names>SO</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Highly conserved tyrosine stabilizes the active state of rhodopsin</article-title><source>PNAS</source><volume>107</volume><fpage>19861</fpage><lpage>19866</lpage><pub-id pub-id-type="doi">10.1073/pnas.1009405107</pub-id><pub-id pub-id-type="pmid">21041664</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulati</surname><given-names>A</given-names></name><name><surname>Sunila</surname><given-names>ES</given-names></name><name><surname>Kuttan</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IRL-1620, an endothelin-B receptor agonist, enhanced radiation induced reduction in tumor volume in dalton’s lymphoma ascites tumor model</article-title><source>Arzneimittel-Forschung</source><volume>62</volume><fpage>14</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1295430</pub-id><pub-id pub-id-type="pmid">22331757</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haryono</surname><given-names>A</given-names></name><name><surname>Ramadhiani</surname><given-names>R</given-names></name><name><surname>Ryanto</surname><given-names>GRT</given-names></name><name><surname>Emoto</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Endothelin and the cardiovascular system: the long journey and where we are going</article-title><source>Biology</source><volume>11</volume><elocation-id>759</elocation-id><pub-id pub-id-type="doi">10.3390/biology11050759</pub-id><pub-id pub-id-type="pmid">35625487</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>M</given-names></name><name><surname>Hibbs</surname><given-names>RE</given-names></name><name><surname>Gouaux</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A fluorescence-detection size-exclusion chromatography-based thermostability assay for membrane protein precrystallization screening</article-title><source>Structure</source><volume>20</volume><fpage>1293</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1016/j.str.2012.06.009</pub-id><pub-id pub-id-type="pmid">22884106</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Iliopoulos-Tsoutsouvas</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Brust</surname><given-names>CA</given-names></name><name><surname>Nikas</surname><given-names>SP</given-names></name><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Grim</surname><given-names>TW</given-names></name><name><surname>Benchama</surname><given-names>O</given-names></name><name><surname>Stahl</surname><given-names>EL</given-names></name><name><surname>Zvonok</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Bohn</surname><given-names>LM</given-names></name><name><surname>Makriyannis</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Z-J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures</article-title><source>Cell</source><volume>180</volume><fpage>655</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.01.008</pub-id><pub-id pub-id-type="pmid">32004463</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Manglik</surname><given-names>A</given-names></name><name><surname>Venkatakrishnan</surname><given-names>AJ</given-names></name><name><surname>Laeremans</surname><given-names>T</given-names></name><name><surname>Feinberg</surname><given-names>EN</given-names></name><name><surname>Sanborn</surname><given-names>AL</given-names></name><name><surname>Kato</surname><given-names>HE</given-names></name><name><surname>Livingston</surname><given-names>KE</given-names></name><name><surname>Thorsen</surname><given-names>TS</given-names></name><name><surname>Kling</surname><given-names>RC</given-names></name><name><surname>Granier</surname><given-names>S</given-names></name><name><surname>Gmeiner</surname><given-names>P</given-names></name><name><surname>Husbands</surname><given-names>SM</given-names></name><name><surname>Traynor</surname><given-names>JR</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Steyaert</surname><given-names>J</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural insights into µ-opioid receptor activation</article-title><source>Nature</source><volume>524</volume><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1038/nature14886</pub-id><pub-id pub-id-type="pmid">26245379</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Raimondi</surname><given-names>F</given-names></name><name><surname>Kadji</surname><given-names>FMN</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name><name><surname>Kishi</surname><given-names>T</given-names></name><name><surname>Uwamizu</surname><given-names>A</given-names></name><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Shinjo</surname><given-names>Y</given-names></name><name><surname>Ishida</surname><given-names>S</given-names></name><name><surname>Arang</surname><given-names>N</given-names></name><name><surname>Kawakami</surname><given-names>K</given-names></name><name><surname>Gutkind</surname><given-names>JS</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><name><surname>Russell</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Illuminating G-protein-coupling selectivity of GPCRs</article-title><source>Cell</source><volume>177</volume><fpage>1933</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.044</pub-id><pub-id pub-id-type="pmid">31160049</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izume</surname><given-names>T</given-names></name><name><surname>Miyauchi</surname><given-names>H</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Crystal structure of human endothelin ETB receptor in complex with sarafotoxin S6b</article-title><source>Biochemical and Biophysical Research Communications</source><volume>528</volume><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.12.091</pub-id><pub-id pub-id-type="pmid">32001000</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>HE</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Suomivuori</surname><given-names>C-M</given-names></name><name><surname>Kadji</surname><given-names>FMN</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><name><surname>Krishna Kumar</surname><given-names>K</given-names></name><name><surname>Fonseca</surname><given-names>R</given-names></name><name><surname>Hilger</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Latorraca</surname><given-names>NR</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name><name><surname>Skiniotis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Conformational transitions of a neurotensin receptor 1–gi1 complex</article-title><source>Nature</source><volume>572</volume><fpage>80</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1337-6</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Che</surname><given-names>T</given-names></name><name><surname>Panova</surname><given-names>O</given-names></name><name><surname>DiBerto</surname><given-names>JF</given-names></name><name><surname>Lyu</surname><given-names>J</given-names></name><name><surname>Krumm</surname><given-names>BE</given-names></name><name><surname>Wacker</surname><given-names>D</given-names></name><name><surname>Robertson</surname><given-names>MJ</given-names></name><name><surname>Seven</surname><given-names>AB</given-names></name><name><surname>Nichols</surname><given-names>DE</given-names></name><name><surname>Shoichet</surname><given-names>BK</given-names></name><name><surname>Skiniotis</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor</article-title><source>Cell</source><volume>182</volume><fpage>1574</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.024</pub-id><pub-id pub-id-type="pmid">32946782</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nishizawa</surname><given-names>T</given-names></name><name><surname>Kadji</surname><given-names>FMN</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-Em structure of the human PAC1 receptor coupled to an engineered heterotrimeric G protein</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>27</volume><fpage>274</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1038/s41594-020-0386-8</pub-id><pub-id pub-id-type="pmid">32157248</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>Y</given-names></name><name><surname>Baba</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Endothelin-Induced cytoskeletal actin re-organization in cultured astrocytes: inhibition by C3 ADP-ribosyltransferase</article-title><source>Glia</source><volume>16</volume><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-1136(199604)16:4&lt;342::AID-GLIA6&gt;3.0.CO;2-1</pub-id><pub-id pub-id-type="pmid">8721674</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Endothelin ETB receptor-mediated astrocytic activation: pathological roles in brain disorders</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>4333</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22094333</pub-id><pub-id pub-id-type="pmid">33919338</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Paknejad</surname><given-names>N</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Kihara</surname><given-names>Y</given-names></name><name><surname>Ray</surname><given-names>M</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Hite</surname><given-names>RK</given-names></name><name><surname>Huang</surname><given-names>X-Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>731</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28417-2</pub-id><pub-id pub-id-type="pmid">35136060</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maguire</surname><given-names>JJ</given-names></name><name><surname>Davenport</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Endothelin at 25-new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR review 12</article-title><source>British Journal of Pharmacology</source><volume>171</volume><fpage>5555</fpage><lpage>5572</lpage><pub-id pub-id-type="doi">10.1111/bph.12874</pub-id><pub-id pub-id-type="pmid">25131455</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manglik</surname><given-names>A</given-names></name><name><surname>Kruse</surname><given-names>AC</given-names></name><name><surname>Kobilka</surname><given-names>TS</given-names></name><name><surname>Thian</surname><given-names>FS</given-names></name><name><surname>Mathiesen</surname><given-names>JM</given-names></name><name><surname>Sunahara</surname><given-names>RK</given-names></name><name><surname>Pardo</surname><given-names>L</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name><name><surname>Granier</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Crystal structure of the µ-opioid receptor bound to a morphinan antagonist</article-title><source>Nature</source><volume>485</volume><fpage>321</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/nature10954</pub-id><pub-id pub-id-type="pmid">22437502</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagiri</surname><given-names>C</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Kadji</surname><given-names>FMN</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Crystal structure of human endothelin ETB receptor in complex with peptide inverse agonist IRL2500</article-title><source>Communications Biology</source><volume>2</volume><elocation-id>236</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-019-0482-7</pub-id><pub-id pub-id-type="pmid">31263780</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>H</given-names></name><name><surname>Isshiki</surname><given-names>K</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name><name><surname>Maehira</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Masuda</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Hohsaka</surname><given-names>T</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Matsuura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cell-Free synthesis of human endothelin receptors and its application to ribosome display</article-title><source>Analytical Chemistry</source><volume>94</volume><fpage>3831</fpage><lpage>3839</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.1c04714</pub-id><pub-id pub-id-type="pmid">35188389</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nureki</surname><given-names>I</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Demura</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cryo-Em structures of the β3 adrenergic receptor bound to solabegron and isoproterenol</article-title><source>Biochemical and Biophysical Research Communications</source><volume>611</volume><fpage>158</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2022.04.065</pub-id><pub-id pub-id-type="pmid">35489202</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>HH</given-names></name><name><surname>Miyauchi</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Raimondi</surname><given-names>F</given-names></name><name><surname>Tsujimoto</surname><given-names>H</given-names></name><name><surname>Kusakizako</surname><given-names>T</given-names></name><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Suno</surname><given-names>R</given-names></name><name><surname>Nomura</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Iwata</surname><given-names>S</given-names></name><name><surname>Nishizawa</surname><given-names>T</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cryo-Em structure of the human MT1–gi signaling complex</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>28</volume><fpage>694</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1038/s41594-021-00634-1</pub-id><pub-id pub-id-type="pmid">34354246</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuta</surname><given-names>A</given-names></name><name><surname>Tani</surname><given-names>K</given-names></name><name><surname>Nishimura</surname><given-names>S</given-names></name><name><surname>Fujiyoshi</surname><given-names>Y</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Thermostabilization of the human endothelin type B receptor</article-title><source>Journal of Molecular Biology</source><volume>428</volume><fpage>2265</fpage><lpage>2274</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2016.03.024</pub-id><pub-id pub-id-type="pmid">27038509</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname><given-names>A</given-names></name><name><surname>Rubinstein</surname><given-names>JL</given-names></name><name><surname>Fleet</surname><given-names>DJ</given-names></name><name><surname>Brubaker</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination</article-title><source>Nature Methods</source><volume>14</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4169</pub-id><pub-id pub-id-type="pmid">28165473</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranjan</surname><given-names>AK</given-names></name><name><surname>Gulati</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sovateltide mediated endothelin B receptors agonism and curbing neurological disorders</article-title><source>International Journal of Molecular Sciences</source><volume>23</volume><elocation-id>3146</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23063146</pub-id><pub-id pub-id-type="pmid">35328566</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>SGF</given-names></name><name><surname>DeVree</surname><given-names>BT</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Kruse</surname><given-names>AC</given-names></name><name><surname>Chung</surname><given-names>KY</given-names></name><name><surname>Kobilka</surname><given-names>TS</given-names></name><name><surname>Thian</surname><given-names>FS</given-names></name><name><surname>Chae</surname><given-names>PS</given-names></name><name><surname>Pardon</surname><given-names>E</given-names></name><name><surname>Calinski</surname><given-names>D</given-names></name><name><surname>Mathiesen</surname><given-names>JM</given-names></name><name><surname>Shah</surname><given-names>STA</given-names></name><name><surname>Lyons</surname><given-names>JA</given-names></name><name><surname>Caffrey</surname><given-names>M</given-names></name><name><surname>Gellman</surname><given-names>SH</given-names></name><name><surname>Steyaert</surname><given-names>J</given-names></name><name><surname>Skiniotis</surname><given-names>G</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Sunahara</surname><given-names>RK</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Crystal structure of the β2 adrenergic receptor-Gs protein complex</article-title><source>Nature</source><volume>477</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1038/nature10361</pub-id><pub-id pub-id-type="pmid">21772288</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ring</surname><given-names>AM</given-names></name><name><surname>Manglik</surname><given-names>A</given-names></name><name><surname>Kruse</surname><given-names>AC</given-names></name><name><surname>Enos</surname><given-names>MD</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody</article-title><source>Nature</source><volume>502</volume><fpage>575</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1038/nature12572</pub-id><pub-id pub-id-type="pmid">24056936</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosanò</surname><given-names>L</given-names></name><name><surname>Spinella</surname><given-names>F</given-names></name><name><surname>Bagnato</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Endothelin 1 in cancer: biological implications and therapeutic opportunities</article-title><source>Nature Reviews. Cancer</source><volume>13</volume><fpage>637</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1038/nrc3546</pub-id><pub-id pub-id-type="pmid">23884378</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name><name><surname>Takuwa</surname><given-names>Y</given-names></name><name><surname>Miyazaki</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Masaki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor</article-title><source>Nature</source><volume>348</volume><fpage>732</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1038/348732a0</pub-id><pub-id pub-id-type="pmid">2175397</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nishizawa</surname><given-names>T</given-names></name><name><surname>Okuta</surname><given-names>A</given-names></name><name><surname>Tani</surname><given-names>K</given-names></name><name><surname>Dohmae</surname><given-names>N</given-names></name><name><surname>Fujiyoshi</surname><given-names>Y</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Activation mechanism of endothelin ETB receptor by endothelin-1</article-title><source>Nature</source><volume>537</volume><fpage>363</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1038/nature19319</pub-id><pub-id pub-id-type="pmid">27595334</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Nishizawa</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Kadji</surname><given-names>FMN</given-names></name><name><surname>Okuta</surname><given-names>A</given-names></name><name><surname>Tani</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><name><surname>Fujiyoshi</surname><given-names>Y</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>X-Ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>24</volume><fpage>758</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3450</pub-id><pub-id pub-id-type="pmid">28805809</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shihoya</surname><given-names>W</given-names></name><name><surname>Izume</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Kadji</surname><given-names>FMN</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><name><surname>Nishizawa</surname><given-names>T</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Crystal structures of human ETB receptor provide mechanistic insight into receptor activation and partial activation</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4711</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-07094-0</pub-id><pub-id pub-id-type="pmid">30413709</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Paknejad</surname><given-names>N</given-names></name><name><surname>Dey</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>M-Y</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><name><surname>Jordan</surname><given-names>KD</given-names></name><name><surname>Eng</surname><given-names>ET</given-names></name><name><surname>Ernst</surname><given-names>OP</given-names></name><name><surname>Meyerson</surname><given-names>JR</given-names></name><name><surname>Hite</surname><given-names>RK</given-names></name><name><surname>Walz</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>X-Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis of the activation of heterotrimeric Gs-protein by isoproterenol-bound β1-adrenergic receptor</article-title><source>Molecular Cell</source><volume>80</volume><fpage>59</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.08.001</pub-id><pub-id pub-id-type="pmid">32818430</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tencé</surname><given-names>M</given-names></name><name><surname>Ezan</surname><given-names>P</given-names></name><name><surname>Amigou</surname><given-names>E</given-names></name><name><surname>Giaume</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Increased interaction of connexin43 with zonula occludens-1 during inhibition of gap junctions by G protein-coupled receptor agonists</article-title><source>Cellular Signalling</source><volume>24</volume><fpage>86</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2011.08.006</pub-id><pub-id pub-id-type="pmid">21872657</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatakrishnan</surname><given-names>AJ</given-names></name><name><surname>Deupi</surname><given-names>X</given-names></name><name><surname>Lebon</surname><given-names>G</given-names></name><name><surname>Tate</surname><given-names>CG</given-names></name><name><surname>Schertler</surname><given-names>GF</given-names></name><name><surname>Babu</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular signatures of G-protein-coupled receptors</article-title><source>Nature</source><volume>494</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/nature11896</pub-id><pub-id pub-id-type="pmid">23407534</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>MA</given-names></name><name><surname>Coleman</surname><given-names>DE</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Iñiguez-Lluhi</surname><given-names>JA</given-names></name><name><surname>Posner</surname><given-names>BA</given-names></name><name><surname>Gilman</surname><given-names>AG</given-names></name><name><surname>Sprang</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>The structure of the G protein heterotrimer Gi alpha 1 beta 1 gamma 2</article-title><source>Cell</source><volume>83</volume><fpage>1047</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90220-1</pub-id><pub-id pub-id-type="pmid">8521505</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Yun</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptor</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>5064</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-25364-2</pub-id><pub-id pub-id-type="pmid">34417468</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cryo-em structure of the human histamine H1 receptor/gq complex</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>e2</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-22427-2</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Ikuta</surname><given-names>T</given-names></name><name><surname>Kawakami</surname><given-names>K</given-names></name><name><surname>Kise</surname><given-names>R</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>M-X</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Cai</surname><given-names>X-H</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism</article-title><source>Nature Chemical Biology</source><volume>18</volume><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1038/s41589-021-00930-3</pub-id><pub-id pub-id-type="pmid">34937912</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Pei</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Hao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z-J</given-names></name><name><surname>Hua</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Structural basis for strychnine activation of human bitter taste receptor TAS2R46</article-title><source>Science</source><volume>377</volume><fpage>1298</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1126/science.abo1633</pub-id><pub-id pub-id-type="pmid">36108005</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>M</given-names></name><name><surname>Kurihara</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Tomobe</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Mitsui</surname><given-names>Y</given-names></name><name><surname>Yazaki</surname><given-names>Y</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Masaki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>A novel potent vasoconstrictor peptide produced by vascular endothelial cells</article-title><source>Nature</source><volume>332</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1038/332411a0</pub-id><pub-id pub-id-type="pmid">2451132</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Shao</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structures of signaling complexes of lipid receptors S1PR1 and S1PR5 reveal mechanisms of activation and drug recognition</article-title><source>Cell Research</source><volume>31</volume><fpage>1263</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1038/s41422-021-00566-x</pub-id><pub-id pub-id-type="pmid">34526663</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>XE</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Melcher</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>M-W</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Molecular recognition of morphine and fentanyl by the human μ-opioid receptor</article-title><source>Cell</source><volume>185</volume><fpage>4361</fpage><lpage>4375</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.09.041</pub-id><pub-id pub-id-type="pmid">36368306</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zivanov</surname><given-names>J</given-names></name><name><surname>Nakane</surname><given-names>T</given-names></name><name><surname>Forsberg</surname><given-names>BO</given-names></name><name><surname>Kimanius</surname><given-names>D</given-names></name><name><surname>Hagen</surname><given-names>WJ</given-names></name><name><surname>Lindahl</surname><given-names>E</given-names></name><name><surname>Scheres</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>New tools for automated high-resolution cryo-EM structure determination in RELION-3</article-title><source>eLife</source><volume>7</volume><elocation-id>e42166</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.42166</pub-id><pub-id pub-id-type="pmid">30412051</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85821.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Drew</surname><given-names>David</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f0yaq80</institution-id><institution>Stockholm University</institution></institution-wrap><country>Sweden</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2023.01.12.523720" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2023.01.12.523720"/></front-stub><body><p>By combining NanoBiT tethering and FSEC methodology, the authors present a useful strategy for the efficient expression and purification of the GPCR-G-protein complex, as demonstrated here by the cryo-EM structure of human ETB in complex with the vasoconstrictioning peptide ET-1 and the inhibitory G-protein (Gi). The ETB-Gi-protein complex provides valuable and convincing data on how ET-1 binding is coupled to Gi-protein binding. The complex structure is solid and will appeal to the GPCR and pharmacology communities.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85821.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Drew</surname><given-names>David</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f0yaq80</institution-id><institution>Stockholm University</institution></institution-wrap><country>Sweden</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Drew</surname><given-names>David</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f0yaq80</institution-id><institution>Stockholm University</institution></institution-wrap><country>Sweden</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Shukla</surname><given-names>Arun</given-names></name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2023.01.12.523720">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2023.01.12.523720v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Cryo-EM structure of the endothelin-1-ETB-Gi complex&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including David Drew as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Kenton Swartz as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Arun Shukla (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Overall, this is an excellent manuscript. Please consider the following comments in a revised version of the manuscript.</p><p>1. Regarding Figure 3B. It might true helpful to also include the amount of buried SA of the Gi interaction to better compare the extent of interaction between a5 and the different solved G-protein complex structures.</p><p>2. Authors highlight a shallow binding modality of alpha5 helix on the receptor and also corelate it with previous studies. It would be helpful if they also comment the functional implications, if any, for this observation? For example, does it have a role in lose G-protein subtype selectivity of ETbR compared to other GPCR where a deeper insertion is observed?</p><p>3. Please consider commentsing on the use of NanoBIT and if this coupling could influence lipid binding, such as PIP2? Also, we would invite the discussion of the use of this technology in the manuscript for other membrane protein complexes.</p><p>4. Please consider expanding the discussion of their findings beyond the structural biology point of view and the potential implications of this work from a clinical point of view in the background and discussion to add more depth to this manuscript.</p><p>5. &quot;Junk particles&quot; are mentioned in the method section on cryo-EM data processing. While we all use this term in our conversations, I wonder if a better terminology can be used when describing such particles in a research manuscript.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The study by Sano et al. observed detailed G-protein activation by endothelin receptor type B after its activation. This is an important study of an underreported topic that revealed novel findings that could be potentially valuable in various disciplines. However, the reviewer feels that the authors would be better served to expand on the discussion of their findings beyond the structural biology point of view. It would be better if the authors put clinical point of view in the background and discussion to add more value in this manuscript.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85821.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Overall, this is an excellent manuscript. Please consider the following comments in a revised version of the manuscript.</p><p>1. Regarding Figure 3B. It might true helpful to also include the amount of buried SA of the Gi interaction to better compare the extent of interaction between a5 and the different solved G-protein complex structures.</p></disp-quote><p>To correctly calculate the buried surface area, we modeled the ICL2 and ICL3. It should be noted that the density corresponding to ICL3 is weak, not enough to model the side chains and discuss the specific ICL3-G<sub>i</sub> interaction. Thus, we corrected the description of ICL2 as:</p><p>“Moreover, ICL2 forms extensive van der Waals interactions with the αN (Figure S3c), which are not observed in other GPCR-G<sub>i</sub> complexes” (lines 183 to 185), and added the discussion about the buried surface area as:</p><p>“The interacting surface area between the receptor and Gα<sub>i</sub> subunit is 1,196 Å2, which is comparable to those in other GPCR-G<sub>i</sub> complexes (µOR:1,260 Å2. NTS<sub>1</sub>:1,197 Å2. and S1P<sub>1</sub>: 1,376 Å2.<sup>34,38,49</sup>). As described above, ICL2 and TM7 extensively interact with the αN and α5 helix of the Gα<sub>i</sub> subunit, respectively. These interactions are uniquely observed in the ET<sub>B</sub>-G<sub>i</sub> complex and can compensate for the shallow binding of G<sub>i</sub>.” (lines 193 to 198).</p><disp-quote content-type="editor-comment"><p>2. Authors highlight a shallow binding modality of alpha5 helix on the receptor and also corelate it with previous studies. It would be helpful if they also comment the functional implications, if any, for this observation? For example, does it have a role in lose G-protein subtype selectivity of ETbR compared to other GPCR where a deeper insertion is observed?</p></disp-quote><p>We added the functional implication about the shallow Gi coupling as:</p><p>“Since the N7.49P7.50xxY7.53 motif is not conserved in ETB, TM7 undergoes the downward movement upon the Gi binding, resulting in the shallow position of the α5-helix. Thus, the restrictions of the residues in the α5-helix may be less strict, accounting for the G-protein promiscuity of ETB. Since the other promiscuous GPCRs (e.g., NTS1) preserve the N7.49P7.50xxY7.53 motif, the proposed mechanism for G-protein promiscuity may be unique to ETB” (lines 226 to 233).</p><disp-quote content-type="editor-comment"><p>3. Please consider commentsing on the use of NanoBIT and if this coupling could influence lipid binding, such as PIP2? Also, we would invite the discussion of the use of this technology in the manuscript for other membrane protein complexes.</p></disp-quote><p>In this study, linkers of sufficient length are inserted between LgBiT and the receptor and between HiBiT and Gβ, respectively. We suppose tethering strategy does not tightly anchor the complex, but only contributes to increasing the proportion of the complex by locate G protein around the receptor constantly. Recently, several papers have employed NanoBiT tethering strategies. In most of them, no density corresponding to NanoBiT has been observed, however, we suppose the tethering strategy also would have had little effect on the structure of the complex in this study. We added the above discussion as:</p><p>“The tethering strategy only increases the proportion of the complex by constantly placing the G protein around the receptor rather than tightly anchoring the complex, suggesting that the fused G system has minimal effect on the complex structure. It should be noted that the potential artifacts resulting from the tethering strategy cannot be entirely ruled out. The hybrid approach we have developed, combining NanoBiT tethering and FSEC methodology, is an effective option for comprehensive structural analysis of various other membrane protein complexes.” (lines 204 to 211).</p><disp-quote content-type="editor-comment"><p>4. Please consider expanding the discussion of their findings beyond the structural biology point of view and the potential implications of this work from a clinical point of view in the background and discussion to add more depth to this manuscript.</p></disp-quote><p>We appreciate reviewer’s constructive remarks. Based on the suggestion, we added clinical details of endothelins in the introduction (lines 77 to 92), and the relationship between our study and clinical application in discussion (lines 212 to 220).</p><disp-quote content-type="editor-comment"><p>5. &quot;Junk particles&quot; are mentioned in the method section on cryo-EM data processing. While we all use this term in our conversations, I wonder if a better terminology can be used when describing such particles in a research manuscript.</p></disp-quote><p>Based on the suggestion, we corrected the wording to carbon edge and ice contamination (line 310).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The study by Sano et al. observed detailed G-protein activation by endothelin receptor type B after its activation. This is an important study of an underreported topic that revealed novel findings that could be potentially valuable in various disciplines. However, the reviewer feels that the authors would be better served to expand on the discussion of their findings beyond the structural biology point of view. It would be better if the authors put clinical point of view in the background and discussion to add more value in this manuscript.</p></disp-quote><p>We appreciate reviewer’s constructive remarks. Based on the suggestion, we added clinical details of endothelins in the introduction (lines 77 to 92), and the relationship between our study and clinical application in discussion (lines 212 to 220).</p></body></sub-article></article>